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As a science, immunology has now matured 
to the point where the tremendous com-
plexities of the immune system are apparent 
for the first time. This new awareness of the 
daunting orchestration of antigen recogni-
tion, and the tempo, magnitude, duration, 
and  character  of  the  response,  which  is 
controlled by leukocytotrophic hormones, 
has become possible only within the past 
30 years, as a result of the era of molecular 
immunology. In particular, we have rec-
ognized the complexities as a result of the 
capacity to delete or insert genes encoding 
important immunological molecules that 
have  been  discovered,  so  that  we  could 
observe their effects on the whole immune 
system in intact animals. Thus, the effects of 
the manipulation of individual genes often 
results in obvious immunological dysfunc-
tion that lead to lethal consequences. Other 
defects are more subtle, but often over time 
lead to equally devastating disruption of the 
immune system. Consequently, it is now 
evident that antigen recognition results in 
the activation of exquisite negative feedback 
loops in addition to the generation of mar-
velously effective immune responses. Thus, 
whether  a  detectable  systemic  immune 
response occurs or not is decided by the 
summation of these positive and negative 
molecular pathways.
It is also evident that genetic approaches 
can only go so far in providing information 
about the complex circuitry that results in 
immunological recognition and response. 
To progress in the future, it is clear that 
immunology  will  have  to  take  chapters 
from  the  neuroscientists,  and  delve  into 
the biophysics of intermolecular interac-
tions. Thus, new ways of monitoring and 
measuring molecular concentrations and 
molecular changes, such as phosphoryla-
tions with their consequent conformational 
changes, will be necessary to discern how 
and why cellular behavior changes. In this 
regard,  further  reductionist  approaches 
must be used at the single cell level, probing 
for molecular changes. Although Leonard 
Herzenberg introduced the flow cytometer 
to immunology almost 40 years ago (Julius 
et al., 1972), for the most part this meth-
odology has only been used to illustrate 
the  complexity  of  cell  populations,  even 
though it is possible to examine individual 
cells. The capacity to monitor and quantify 
intracellular and cell surface molecules with 
fluorescent monoclonal antibodies has been 
important in discerning how cell differen-
tiation and signaling occurs (Jung et al., 
1993; Perez and Nolan, 2002; Feinerman 
et  al.,  2008).  However,  the  number  of 
molecules that can be monitored simulta-
neously is limited by the number of fluo-
rescent molecules. Now, the combination 
of flow cytometry and inductively coupled 
time-of-flight mass spectroscopy (Bandura 
et al., 2009) promises to be even more fruit-
ful because it will be possible to determine 
the concentration and status of as many as 
30 individual molecules within individual 
cells, and to relate this information to cel-
lular behavior.
Although information as to the behavior 
of individual molecules in individual cells is 
necessary for a true reductionist approach 
to immunology, it is also important not to 
forget that the systemic immune response is 
determined by cell populations. Moreover, 
the  various  heterogeneous  cells  within 
the populations influence one another by 
expressing and metabolizing the many cell 
surface as well as secreted molecules. In this 
regard, it is no longer sufficient to view the 
immune system as passive, regulated totally 
from without upon introduction of antigenic 
molecules, a concept introduced by Burnet 
(1957). The cells of the system react to anti-
genic stimulation via expression of genes 
that  encode  leukocytotropic  hormones, 
cell surface ligands, receptors, intracellular 
signaling molecules, and transcription fac-
tors, all of which determine the expression 
of genetic programs that ultimately deter-
mine cellular responses. Thus, the immune 
system is like other organ systems, being 
controlled by its own internally regulated 
hormone-like  and    neurotransmitter-like 
circuitry, and not solely by external anti-
gens. The   challenge that lies ahead is to 
unravel how this   infinitely complex   cellular 
and  molecular  circuitry  eventually  dis-
criminates between self and non-self, and 
thereby leads to a recognizable and measur-
able immune response. It is clear that cells 
respond to ligand/receptor interactions at 
the cell surface in a quantal (all-or-none) 
manner, and somehow this digital informa-
tion is transferred from the cell surface to 
the cytoplasm and to the nucleus, resulting 
in quantal gene expression (Smith, 2004, 
2006, 2010). In this regard, systems biology 
approaches promise to provide much more 
data to decipher.
All of these issues become of paramount 
importance when considering disorders of 
the  immune  system  that  lead  to  immu-
nological diseases. We have already made 
great progress in understanding the genetic 
and molecular defects that lead to primary 
as well as secondary immunodeficiencies, 
autoimmunity,  allergies,  and  malignan-
cies in the immune system. However, our 
abilities and capacities to therapeutically 
intervene in these disorders remains rudi-
mentary.  The  dream  to  use  monoclonal 
antibodies as therapeutics has finally been 
realized, and pharmaceutical companies are 
gradually transforming from being solely 
focused on small molecules to large mole-
cules, particularly antibodies and cytokines 
targeting cells and extracellular molecules. 
However, in addition to these new thera-
peutics, we also need to generate more new 
and novel small molecular drugs that target 
specific intracellular molecules that we have 
uncovered as important for immunity.
One of the challenges ahead to more 
effectively treat immune system disorders is 
to combine the large molecular therapeutics 
that thus far have been utilized in the clinic 
only as monotherapies. The way forward 
has already been illuminated by the com-
bination of anti-inflammatory agents with 
immunosuppressive drugs, which has cre-
ated a revolution in the treatment of chronic 
inflammatory diseases such as rheumatoid 
arthritis (Maini et al., 1998; Lipsky et al., 
2000). Other combinations such as anti-
inflammatory  and  immunostimulatory 
agents have yet to make it to the clinic, but Smith  Immunology Grand Challenges
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of fantasy. Thus, another of our challenges 
is to understand the immune system well 
enough so that we can produce vaccines 
at  will,  which  may  well  finally  prevent 
and  treat  all  infectious  diseases,  as  well 
as cancer!
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they promise to provide for the ability to 
boost  immune  responses  with  fewer,  or 
even completely absent inflammatory side 
effects. These ideas will undoubtedly form 
the basis of many new clinical trials that 
will lead to the acceptance, distribution and 
widespread use of immunotherapies. Who 
knows, they may even lead to a new kind 
of practitioner, one who understands the 
complexities of the immune system, can 
detect the abnormalities and can actually 
intervene to correct them!
One of the dreams that Pasteur prom-
ulgated was the hope that all infectious 
diseases could one day be prevented and 
treated  simply  by  vaccination. Although 
Pasteur introduced the notion of attenu-
ated  live  prophylactic  vaccines  in  1880 
(Pasteur, 1880; Pasteur et al., 1881), and 
the idea of therapeutic vaccines for rabies 
in 1885 (Pasteur, 1885), we still cannot pro-
duce vaccines at will. Witness the saga of 
the difficulty of creating an HIV vaccine 
in our time (Smith, 2003). Even though we 
can determine the primary, secondary and 
tertiary structure of the site on the antigen 
molecule that binds to the receptor on the 
target cell surface, knowing this informa-
tion still is not enough to develop a vac-
cine capable of eliciting virus neutralizing 
antibodies. Moreover, therapeutic vaccines 
for HIV and cancer are still in the realm 